Merus N.V.

Merus N.V.verified

MRUS

Price:

$96.22

Market Cap:

$7.30B

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients ...[Read more]

Industry

Biotechnology

IPO Date

2016-05-19

Stock Exchange

NASDAQ

Ticker

MRUS

The Enterprise Value as of December 2025 (TTM) for Merus N.V. (MRUS) is 6.93B

According to Merus N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.93B. This represents a change of 80.11% compared to the average of 3.85B of the last 4 quarters.

Merus N.V. (MRUS) Historical Enterprise Value (quarterly & annually)

How has MRUS Enterprise Value performed in the past?

The mean historical Enterprise Value of Merus N.V. over the last ten years is 620.06M. The current 6.93B Enterprise Value has changed 111.71% with respect to the historical average. Over the past ten years (40 quarters), MRUS's Enterprise Value was at its highest in in the September 2025 quarter at 6.76B. The Enterprise Value was at its lowest in in the June 2016 quarter at 8.80M.

Quarterly (TTM)
Annual

Average

620.06M

Median

279.79M

Minimum

82.52M

Maximum

2.42B

Merus N.V. (MRUS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Merus N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 180.16%

Maximum Annual Enterprise Value = 2.42B

Minimum Annual Increase = -59.91%

Minimum Annual Enterprise Value = 82.52M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20242.42B97.11%
20231.23B118.73%
2022560.62M-43.43%
2021991.02M180.16%
2020353.73M137.99%
2019148.63M38.08%
2018107.64M30.45%
201782.52M-59.91%
2016205.84M91.96%
2015107.23M-15.28%

Merus N.V. (MRUS) Average Enterprise Value

How has MRUS Enterprise Value performed in the past?

The current Enterprise Value of Merus N.V. (MRUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

1.40B

5-year avg

1.11B

10-year avg

620.06M

Merus N.V. (MRUS) Enterprise Value vs. Peers

How is MRUS’s Enterprise Value compared to its peers?

Merus N.V.’s Enterprise Value is less than Cytokinetics, Incorporated (8.73B), less than Nuvalent, Inc. (7.65B), less than Abivax S.A. (7.35B), less than Axsome Therapeutics, Inc. (7.35B), less than Metsera, Inc. (6.98B), less than Rhythm Pharmaceuticals, Inc. (7.15B), less than Jazz Pharmaceuticals plc (9.90B), less than Halozyme Therapeutics, Inc. (8.49B), less than Corcept Therapeutics Incorporated (8.79B), less than Avidity Biosciences, Inc. (9.15B),

Build a custom stock screener for Merus N.V. (MRUS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Merus N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Merus N.V. (MRUS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Merus N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Merus N.V.'s Enterprise Value?

What is the highest Enterprise Value for Merus N.V. (MRUS)?

What is the 3-year average Enterprise Value for Merus N.V. (MRUS)?

What is the 5-year average Enterprise Value for Merus N.V. (MRUS)?

How does the current Enterprise Value for Merus N.V. (MRUS) compare to its historical average?